Related Experiment Videos
[Clinical studies of cefsulodin in the pediatric field]
Insights
Cefsulodin (CFS) demonstrates favorable pharmacokinetics and clinical effectiveness in treating pediatric P. aeruginosa infections. This antibiotic showed a 75% efficacy rate with no observed side effects, indicating its potential utility.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Antimicrobial Agents
Background:
- Pseudomonas aeruginosa (P. aeruginosa) infections pose a significant challenge in pediatric care, particularly in patients with underlying conditions like cystic fibrosis.
- Cefsulodin (CFS), a cephalosporin antibiotic, has been evaluated for its efficacy and safety in treating pediatric bacterial infections.
Observation:
- Pharmacokinetic analysis in a pediatric patient showed specific serum concentrations of CFS post-intravenous administration and a urinary recovery rate of 66.2% within 6 hours.
- Clinical trials involved pediatric patients with P. aeruginosa infections, including bronchitis with cystic fibrosis, pyelonephritis, and measles pneumonia, treated with CFS via intravenous routes.
- Dosages ranged from 47 to 86 mg/kg/day for 5 to 11 days, administered multiple times daily.
Findings:
- CFS achieved a 75.0% effectiveness rate in treating P. aeruginosa infections across various pediatric conditions.
- Treatment outcomes were rated as 'good' in 3 out of 4 cases, with one case of measles pneumonia showing a 'fair' response.
- No adverse side effects or abnormal laboratory findings were reported during the administration of Cefsulodin.
Implications:
- Cefsulodin (CFS) is identified as a potentially useful and safe therapeutic option for managing P. aeruginosa infections in pediatric patients.
- The findings support the further investigation and potential clinical application of CFS in pediatric infectious disease management.
- Further research could explore CFS in broader pediatric populations and different infection types caused by P. aeruginosa.
Abstract:
Pharmacokinetic and clinical evaluations of cefsulodin (CFS) were made and the following results were obtained. 1. Pharmacokinetic study Three hundred fifty grams of CFS (20 mg/kg) was administered by 30 minutes intravenous drip infusion to 7 years old child (17.5 kg in weight). Serum concentrations of CFS at the end of the infusion and 1,1.5,2.5,6.5 hours thereafter were 46.0,44.9,23.0,11.9 mcg/ml and 0.6 mcg/ml respectively. Urinary recovery rate until 6 hours from the start of infusion was 66.2%. 2. Clinical study CFS was administered to the case of bronchitis with cystic fibrosis of the pancreas and bronchiectasia (treatment was made 2 times), and each 1 case of pyelonephritis with renal calculus and measles pneumonia with infantile spasm. All infections were caused by P. aeruginosa and administration and dosage of CFS was 47 to 86 mg/kg/day, 2 to 4 times daily by intravenous injection or intravenous drip infusion for 5 to 11 days. Result was good in 3 infections (2 cases) and fair in 1 case, i.e. measles pneumonia. Effectiveness rate was 75.0%. Side effect as well as abnormal change of laboratory findings were not observed. Thus, CFS is considered to be the useful drug for the treatment of pediatric infection caused by P. aeruginosa.